📈 Jumpstart Signal Watchlist — October 27, 2026

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.57 is 9% below 3yr high $12.66 · ⏳ SMA200 $9.37 (current price $11.57 is above) · 💰 Market Cap $2.0B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (6.8%)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal? — Yahoo Finance.
🤖 The article discusses Vir’s Gilead collaboration, which includes upfront consideration and potential milestone payments, and notes recent share-price momentum. It also highlights risks to the bullish outlook, including possible study disappointments and regulatory setbacks.
✅ Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? — Zacks.
🤖 The article reviews Gilead’s agreement with Vir to develop three solid-tumor T-cell engager candidates. The upfront and potential milestone payments, plus royalties, offer financial and pipeline upside for Vir.
✅ Gilead and Vir forge $1.9bn pact to develop next-gen T-cell therapies — Yahoo Finance.
🤖 The deal provides Vir with $90 million upfront, potential near-term milestones, and up to $1.74 billion in additional milestone payments and royalties. Gilead will lead later development and commercialization, giving Vir a partner for advancing the candidates.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.42 is 6% below 3yr high $15.26 · ⏳ SMA200 $10.77 (current price $14.42 is above) · 💰 Market Cap $975M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×1).
✅ Bioventus Inc. (NASDAQ:BVS) Stock Has Average Target Price of $16.80 — MarketBeat.
🤖 The article reports a consensus Buy rating from six analysts and an average price target of $16.80. It also notes an October 8 upgrade by Weiss Ratings from Hold to Buy, a positive analyst signal.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 At/above 3yr high $81.23 (current $81.23) · ⏳ SMA200 $56.68 (current price $81.23 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 4/20
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ red violet Climbs 25 Spots to No. 82 on TIME’s America’s Growth Leaders of 2027 List — Yahoo Finance.
🤖 Red Violet was named to TIME’s America’s Growth Leaders of 2027 list at No. 82, up from No. 107 in the inaugural list. The recognition and improved ranking offer a positive signal about the company’s growth.
✅ Red Violet (NASDAQ:RDVT) Sets New 1-Year High — MarketBeat.
🤖 The article reports that RDVT reached a new 52-week high of $82.19 during trading. The price milestone reflects strong recent share performance, though it does not itself establish a change in the company’s fundamentals.
❌ Red Violet (NASDAQ:RDVT) Stock Rating Lowered by Zacks Research — MarketBeat.
🤖 Zacks Research downgraded Red Violet from Strong Buy to Hold, a negative analyst-rating change. The article also notes that the broader analyst consensus remains Moderate Buy and that the company beat quarterly earnings expectations.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $70.53 is 0% below 3yr high $70.74 · ⏳ SMA200 $32.73 (current price $70.53 is above) · 💰 Market Cap $3.6B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.4%)
- 🔔 Strong above EMA50 (20.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×3).
✅ BTIG raises CareDx stock price target to $81 on revenue outlook — Investing.com.
🤖 BTIG raised its price target from $74 to $81 and maintained its Buy rating, citing the revenue outlook. The article also notes CareDx’s previously reported second-quarter results exceeded analyst expectations.
✅ CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 — Business Wire.
🤖 CareDx highlighted clinical data associating elevated AlloSure Kidney results with a nearly threefold higher risk of adverse graft outcomes in certain patients. The release also described study findings that dd-cfDNA monitoring was associated with fewer biopsies, supporting the clinical utility of the company’s testing.
✅ CareDx presents kidney transplant monitoring study results — Investing.com.
🤖 The article reports study findings that dd-cfDNA monitoring was associated with 49% fewer biopsies than surveillance biopsies, with similar reported safety outcomes. It also describes evidence supporting AlloSure Kidney’s ability to identify patients at higher risk of adverse outcomes.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: IDT Corporation provides communications and payment services, including international money transfers, prepaid calling and digital payment products, and wholesale voice and messaging. It also offers point-of-sale and payment-processing tools for independent retailers and cloud-based communications services for businesses.
- 🎯 Current $80.56 is 5% below 3yr high $84.46 · ⏳ SMA200 $58.93 (current price $80.56 is above) · 💰 Market Cap $2.0B
- IDT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (6.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 28% (>20%); ROE 23% (>15%); Low LT D/E 0.02 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (56) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ IDT Q4 Earnings and Revenues Rise as Margins Expand on Strong Growth — Zacks.
🤖 IDT reported higher fourth-quarter revenue, EPS, net income, and adjusted EBITDA, alongside expanded full-year gross margins. The results indicate stronger profitability and growth.
✅ IDT (NYSE:IDT) Hits New 1-Year High - What's Next? — MarketBeat.
🤖 The article notes recent analyst actions, including a Buy rating and higher price target from Freedom Broker and an upgrade to Buy from Weiss Ratings. These rating changes are favorable, though the article also reports the stock’s recent high.
⚪️ IDT CFO Marcelo Fischer sells $760,847 in class B common stock — Investing.com.
🤖 The article reports the CFO’s stock sale, a routine insider transaction that does not by itself establish a directional catalyst for the stock.
⚪️ Idt director Judah Schorr sells $1.12m in class B common stock — Investing.com.
🤖 The article reports a director’s share sale, which is a backward-looking insider transaction and not, on its own, a directional catalyst.
🍭 Bonus (B): 0/10 — Telephone Communications

🏢 What they do: Match Group operates a portfolio of online dating and relationship apps and websites, including Tinder, Hinge, Match, OkCupid, and Plenty of Fish. Its services are designed to help people make meaningful connections and meet potential partners through digital platforms.
- 🎯 Current $43.69 is 6% below 3yr high $46.53 · ⏳ SMA200 $36.36 (current price $43.69 is above) · 💰 Market Cap $10.0B
- MTCH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 43% (>20%); PEG ratio 0.36 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
- ⚠️ RSI reversing from overbought (53) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×1).
✅ Match Group shares jump as Evercore ISI upgrades stock on Tinder recovery — Yahoo Finance.
🤖 Evercore ISI upgraded Match Group to Outperform from In Line and raised its price target from $39 to $53, citing data suggesting Tinder’s user recovery is accelerating. The analyst also raised estimates, anticipating stronger future revenue and adjusted EBITDA.
✅ Should Match Stock's New High Stop You From Buying? — Yahoo Finance.
🤖 The article highlights higher net income, lower costs, and strong Hinge revenue growth as support for Match’s recent share-price gains. It also notes that Tinder revenue slipped, tempering the otherwise favorable fundamentals.
⚪️ Will Tinder’s Radical Rebrand Save Match Group From Permanent Decline? — Yahoo Finance.
🤖 The article weighs Tinder’s global rebrand against ongoing payer and revenue declines, while noting improved engagement indicators and stronger adjusted EBITDA guidance. The mixed picture does not point clearly in one direction for MTCH.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Worthington Enterprises designs and manufactures building and consumer products, including HVAC and water systems, metal roofing and ceiling components, tools, portable propane and helium cylinders, outdoor-living products, and celebration supplies. Its brands include Bernzomatic, Balloon Time, Coleman propane cylinders, Garden Weasel, and LEVEL5 Tools.
- 🎯 Current $63.40 is 6% below 3yr high $67.39 · ⏳ SMA200 $56.19 (current price $63.40 is above) · 💰 Market Cap $3.1B
- WOR passed all filters and shows favorable conditions.

💎 Quality (Q): 57/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 24% (>20%); ROE 16% (>15%); Low LT D/E 0.29 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (⚪️×2).
⚪️ Worthington Enterprises director John McConnell sells $2.57M in shares — Investing.com.
🤖 The article reports a Form 4 disclosure of shares sold after McConnell exercised stock options. This is a report of an insider transaction, not by itself a company-specific operating catalyst.
⚪️ Worthington Enterprises Participating in Baird Global Industrial Conference Following Investor and Analyst Day — GlobeNewswire.
🤖 The company announced participation in an upcoming industrial conference. The announcement provides no new financial results, guidance, or other material catalyst.
🍭 Bonus (B): 0/10 — Steel Works & Blast Furnaces